Dr Reddy's Laboratories (BOM:500124) Interest Expense : ₹-1,711 Mil (TTM As of Mar. 2024)

View and export this data going back to 1992. Start your Free Trial

What is Dr Reddy's Laboratories Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Dr Reddy's Laboratories's interest expense for the three months ended in Mar. 2024 was ₹ -593 Mil. Its interest expense for the trailing twelve months (TTM) ended in Mar. 2024 was ₹-1,711 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Dr Reddy's Laboratories's Operating Income for the three months ended in Mar. 2024 was ₹ 14,462 Mil. Dr Reddy's Laboratories's Interest Expense for the three months ended in Mar. 2024 was ₹ -593 Mil. Dr Reddy's Laboratories's Interest Coverage for the quarter that ended in Mar. 2024 was 24.39. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Dr Reddy's Laboratories Interest Expense Historical Data

The historical data trend for Dr Reddy's Laboratories's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Dr Reddy's Laboratories Interest Expense Chart

Dr Reddy's Laboratories Annual Data

Trend

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Mar24

Interest Expense

Get a 7-Day Free Trial

-983.00

-970.00

-958.00

-1,428.00

-1,711.00

Dr Reddy's Laboratories Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Interest Expense	Get a 7-Day Free Trial															-354.00	-371.00	-353.00	-394.00	-593.00

Dr Reddy's Laboratories Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹-1,711 Mil.

Dr Reddy's Laboratories (BOM:500124) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Dr Reddy's Laboratories's Interest Expense for the three months ended in Mar. 2024 was ₹-593 Mil. Its Operating Income for the three months ended in Mar. 2024 was ₹14,462 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Mar. 2024 was ₹5,990 Mil.

Dr Reddy's Laboratories's Interest Coverage for the quarter that ended in Mar. 2024 is calculated as

Interest Coverage	=	-1	*	Operating Income (Q: Mar. 2024 )	/	Interest Expense (Q: Mar. 2024 )
	=	-1	*	14462	/	-593
	=	24.39

The higher the ratio, the stronger the company's financial strength is.

Dr Reddy's Laboratories (BOM:500124) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Dr Reddy's Laboratories Ltd (BOM:500124) » Definitions » Interest Expense

Traded in Other Exchanges

RDY:USA DRREDDY:India RDDA:Germany RDDA:Germany R1DY34:Brazil

Address

8-2-337, Road No. 3, Banjara Hills, Hyderabad, TG, IND, 500 034

Website

https://www.drreddys.com

Dr. Reddy's is one of the largest generic drug manufacturers in the world. It has a significant presence in North America, a region that makes up roughly half of its generics sales, and it services India (22% of its generics sales), Russia (12%), and certain European and Latin American countries. Beyond simple generics, Dr. Reddy's also has a solid portfolio of injectables which make up 25% of its North America sales. In branded generic markets like India, Dr. Reddy's has established a compelling presence with its strong brand name and earned a top five spot in key therapeutic areas including oncology and gastroenterology. Dr. Reddy's also has an active pharmaceutical ingredient business that manufactures over 150 APIs and sells in over 75 countries.

Dr Reddy's Laboratories (BOM:500124) Headlines

No Headlines